Key Takeaways
- FDA approval of oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, is expected in June.
Unicycive Therapeutics was started by a single person, went public through an IPO in 2021, and four years later is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?